Role of Bile Acids and Gut Bacteria in GI Diseases

胆汁酸和肠道细菌在胃肠道疾病中的作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): The human colon harbors one of the most densely populated bacterial ecosystems known (>1011 bacteria/g feces). Cholic acid (CA) and chenodeoxycholic acid (CDCA) are primary bile acids synthesized from cholesterol in the liver. Bile acids undergo enterohepatic circulation several times each day. Primary bile acids entering the colon are deconjugated and free bile acids are biotransformed to more than 20 different metabolites by gut bacteria. The major biotransformation is 7¿-dehydroxylation (7¿- DeOH) of CA and CDCA yielding the secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA), respectively. Hydrophobic secondary bile acids are highly toxic to mammalian cells and can accumulate to high levels (>70%) in the bile acid pool of some individuals as the human liver cannot 7¿-hydroxylate secondary bile acids. High levels of DCA in blood, bile, and feces have been correlated with an increase risk of colon cancer and cholesterol gallstone disease, in some patients. The formation of secondary bile acids is carried out by a few species of the genus Clostridium and the level of these bacteria in feces is correlated with DCA levels in bile. The biochemical pathway of bile acid 7¿-DeOH has been elucidated by our group. However, many of the genes encoding enzymes in this pathway have not been isolated and characterized nor have the 3D structure of key enzymes in this pathway determined. Some strains of 7¿- dehydroxylating bacteria can convert glucocorticoids into C-19 androgenic compounds and the genes encoding these enzymes have not been isolated. Isolation of these genes is crucial for the development of molecular techniques (RT-PCR) to easily monitor intestinal bile acid and glucocorticoid metabolism and pharmacological or dietary ways to decrease formation of secondary bile acids and C-19 androgenic compounds. Subaim 1A. Identify CA, allo-CA, and glucocorticoid inducible genes from the human bile acid 7¿-dehydroxylating bacterium, Clostridium scindens ATCC 35704, via a wholetranscriptome approach (RNAseq). Subaim 1B. Develop quantitative PCR assays for key genes involved in allo-DCA and C-19 androgen formation. Aim 2. Characterize the allo-CA and glucocorticoid inducible enzymes from Clostridium scindens ATCC 35704 catalyzing the formation of allo-DCA acid and C-19 androgens, respectively. Aim 3: Determine the 3D structure of bile acid 7¿ and 7¿-dehydratases, the rate limiting enzymes in bile acid 7¿/7¿-DeOH, from Clostridium scindens. The results of these studies will give us the tools to carry out clinical studies to determine the most effective ways to decrease DCA in the bile acid pool with the aim of decreasing the risk of colon cancer and cholesterol gallstones, in some patients.
描述(由申请人提供): 人类结肠是已知细菌最密集的生态系统之一(> 1011 个细菌/克粪便) 胆酸 (CA) 和鹅去氧胆酸 (CDCA) 是由肝脏中的胆固醇合成的初级胆汁酸。每天多次进入结肠的初级胆汁酸被肠道细菌生物转化为 20 多种不同的代谢物。 7° CA 和 CDCA 的脱羟基化 (7´- DeOH) 分别产生次级胆汁酸脱氧胆酸 (DCA) 和石胆酸 (LCA) 疏水性次级胆汁酸对哺乳动物细胞具有剧毒,并且可以积累到高水平 (>70)。 %) 存在于某些个体的胆汁酸库中,因为人类肝脏不能 7¿在一些患者中,血液、胆汁和粪便中高含量的 DCA 与结肠癌和胆固醇胆结石疾病的风险增加相关。梭菌属和粪便中这些细菌的水平与胆汁中 DCA 的水平相关 胆汁酸 7¿ -DeOH 已被我们的小组阐明,但是,该途径中的许多编码酶的基因尚未被分离和表征,也没有确定该途径中的一些关键酶的 3D 结构。 - 脱羟基细菌可以将糖皮质激素转化为 C-19 雄激素化合物,而编码这些酶的基因尚未分离出来,这些基因的分离对于分子技术 (RT-PCR) 的发展至关重要,以轻松监测肠道胆汁酸和糖皮质激素的代谢。减少次级胆汁酸和 C-19 雄激素化合物形成的药物或饮食方法。来自人类胆汁酸7的诱导基因-脱羟基细菌,Clostridium scindens ATCC 35704,通过全转录组方法 (Subaim 1B) 对参与异源 DCA 和 C-19 雄激素形成的关键基因进行定量 PCR 检测。 目标 2. 表征异源 CA 和糖皮质激素。来自 Clostridium scindens ATCC 35704 催化的诱导酶分别形成异源 DCA 酸和 C-19 雄激素 目标 3:确定胆汁酸 7¿ 的 3D 结构。和 7¿ -脱水酶,胆汁酸中的限速酶 7¿ /7¿ -DeOH,来自梭状芽孢杆菌,这些研究的结果将为我们提供进行临床研究的工具,以确定减少胆汁酸库中 DCA 的最有效方法,从而降低结肠癌和胆固醇胆结石的风险,在一些患者中。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PHILLIP B HYLEMON其他文献

PHILLIP B HYLEMON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PHILLIP B HYLEMON', 18)}}的其他基金

Sphingolipids in alcoholic liver disease
酒精性肝病中的鞘脂
  • 批准号:
    10608594
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
LncRNA H19 in Cholestatic Liver Diseases
LncRNA H19 在胆汁淤积性肝病中的作用
  • 批准号:
    10202570
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
LncRNA H19 in Cholestatic Liver Diseases
LncRNA H19 在胆汁淤积性肝病中的作用
  • 批准号:
    10909545
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
LncRNA H19 in Cholestatic Liver Diseases
LncRNA H19 在胆汁淤积性肝病中的作用
  • 批准号:
    9750721
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Bile Acid and Sphingosine-1-phosphate Receptor-mediated Signaling in Cholestasis
胆汁酸和 1-磷酸鞘氨醇受体介导的胆汁淤积信号传导
  • 批准号:
    9024718
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Bile Acids and Clostridium scindens Inhibit C. difficile: Role of Secreted Antibacterial Compounds
胆汁酸和梭菌抑制艰难梭菌:分泌的抗菌化合物的作用
  • 批准号:
    9233344
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Role of Bile Acids and Gut Bacteria in GI Diseases
胆汁酸和肠道细菌在胃肠道疾病中的作用
  • 批准号:
    8536579
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Role of Bile Acids and Gut Bacteria in GI Diseases
胆汁酸和肠道细菌在胃肠道疾病中的作用
  • 批准号:
    8324091
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
HIV Protease Inhibitors and Hepatic Lipid Dysregulation
HIV 蛋白酶抑制剂和肝脂质失调
  • 批准号:
    7035831
  • 财政年份:
    2004
  • 资助金额:
    --
  • 项目类别:
HIV Protease Inhibitors and Hepatic Lipid Dysregulation
HIV 蛋白酶抑制剂和肝脂质失调
  • 批准号:
    6799002
  • 财政年份:
    2004
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Mechanistic Studies of Gyrase/Topoisomerase IV-Targeted Antibacterials
旋转酶/拓扑异构酶 IV 靶向抗菌药物的机理研究
  • 批准号:
    10667862
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Mechanisms of HIV fitness and drug resistance inferred from high-resolution molecular dynamics and sequence co-variation models
从高分辨率分子动力学和序列共变模型推断出 HIV 适应性和耐药性的机制
  • 批准号:
    10750627
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Actions of spiropyrimidinetriones against bacterial type II topoisomerases
螺嘧啶三酮对细菌 II 型拓扑异构酶的作用
  • 批准号:
    10750473
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Development of Selective Oxidative Biocatalytic Methods
选择性氧化生物催化方法的发展
  • 批准号:
    10606798
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
New target and new therapy for severe Covid-19 and viral hyperinflammation damage: renalase and renalase agonists
严重Covid-19和病毒性过度炎症损伤的新靶点和新疗法:肾酶和肾酶激动剂
  • 批准号:
    10759030
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了